Physician profile
Steven E Morris
NPI 1033159637
$4,994.06
in general payments reported to CMS, 2019-2025
27 companies · $611 in 2025
The $611 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2021: $759 · 2022: $990 · 2023: $896 · 2024: $1,028 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $802.64 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $578.36 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $515.54 | 2021-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.70 | 2019-2025 | Xifaxan |
| Abbvie INC. | $297.00 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $290.00 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.81 | 2024 | Jardiance |
| Abbott Laboratories | $207.84 | 2024-2025 | Aveir |
| Novartis Pharmaceuticals Corporation | $198.17 | 2019-2025 | |
| Lilly USA, LLC | $179.30 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $146.81 | 2022-2024 | |
| Edwards Lifesciences Corporation | $141.30 | 2024 | |
| Esperion Therapeutics, INC. | $128.57 | 2021 | |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Genzyme Corporation | $125.00 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $125.00 | 2023 | Stelara |
| Boston Scientific Corporation | $109.82 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2021 | |
| Medline Industries LP | $86.19 | 2019 | |
| Exact Sciences Corporation | $80.31 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $35.75 | 2025 | |
| Nevro Corp. | $33.59 | 2024 | Senza |
| Idorsia Pharmaceuticals US INC | $21.91 | 2023 | Quviviq |
| Insightec,INC | $19.87 | 2025 | Exablate |
| Acella Pharmaceuticals, LLC | $19.85 | 2023 | NP Thyroid 60 |
| Urovant Sciences INC | $18.55 | 2022 | |
| Astellas Pharma US INC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.